We've published work in Chemical & Biomedical Imaging covering our development of pemefolacianine (NY-07) to address a critical failure mode in fluorescence-guided surgery. Current FDA-approved probes generate false-positive rates of 25-68% because they accumulate in both tumor and inflammatory tissue, leading to unnecessary resections and surgical complications. NY-07, designed through ML optimization integrated with CADD modeling of antifolate drugs, achieved 8-fold selectivity for tumor over inflammatory tissue. The compound is currently being advanced through Phase II clinical trials by our industrial collaborator Nanjing Nuoyuan Medical Devices following IND approval from both FDA and NMPA.